ArticleJournal of transplantation2026
Does Atherosclerosis Progress Faster After Liver Transplant? A Comparative Study and Analysis of Progression Risk Factors.
Article in Journal of transplantation, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Does Atherosclerosis Progress Faster After Liver Transplant? A Comparative Study and Analysis of Progression Risk Factors.Journal of transplantation · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Cardiovascular disease (CVD) is thought to evolve faster after liver transplantation (LT) due to an increased prevalence of cardiovascular risk (CVR) factors and the use of immunosuppression. The progression of coronary artery calcium score (CACS) in computed tomography is a prognostic biomarker of CVD. There is scarce information about CACS changes after LT or in patients with cirrhosis. Methods: We compared the 5-year progression of CACS in two populations: 75 LT recipients and 20 patients with cirrhosis assessed for LT but who eventually did not undergo LT (non-LT). In both populations, CACS was measured at LT evaluation and 5 years thereafter. Additionally, we studied 1-year post-LT CVR factors and immunosuppression parameters, including cumulative exposure to tacrolimus (CET) as potential predictors of 5-year CACS progression after LT. Results: Both groups were comparable regarding CVR factors, time between CACS, or baseline CACS. CACS increased in both groups, with an annualized progression of 23 Agatston units (AU)/year in LT and 30 AU/year in non-LT ( Conclusion: In LT recipients with optimized control of CVR factors and standard/minimized CET, CACS progression was not faster than in patients with cirrhosis. The association between posttransplant renal function and CACS progression warrants further investigation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.